Correction d'un communiqué du 23.10.2019, 17:55 CET/CEST - Eli Lilly and Company: Q319LillySalesandEarningsPressRelease
Le 23 octobre 2019 à 19:15
Partager
Eli Lilly and Company
Correction d'un communiqué du 23.10.2019, 17:55 CET/CEST - Eli Lilly and Company: Q319LillySalesandEarningsPressRelease
23-Oct-2019 / 19:09 CET/CEST
Information réglementaire transmise par EQS Group.
Le contenu de ce communiqué est de la responsabilité de l'émetteur.
ELI LILLY AND COMPANY FILES A FORM 8-K
INDIANAPOLIS, October 23, 2019, -Eli Lilly and Company (NYSE / Euronext Paris / SIX: LLY)today informs its shareholders that it has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission ("SEC") on October 23, 2019, announcing financial results for the third quarter of 2019.
Lilly makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after Lilly electronically files these documents with, or furnishes them to, the SEC.These documents are posted on Lilly's website at www.lilly.com- under "Investors."
The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at www.sec.gov.
Copies of the above referenced information will also be made available, free of charge, upon written request to the Company's secretary atLilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.
Fichier PDF dépôt réglementaire
Titre du document : Eli Lilly and Company: Files Form 8K Document : http://n.eqs.com/c/fncls.ssp?u=PUAWMILXPW
Eli Lilly and Company figure parmi les principaux groupes pharmaceutiques mondiaux. Le CA par domaine thérapeutique se répartit comme suit :
- endocrinologie (57,7%) : produits pour le traitement de l'ostéoporose, du diabète et des problèmes de croissance ;
- oncologie (19,5%) ;
- maladies immunitaires (11,1%) ;
- neurologie (8,4%) : essentiellement médicaments destinés au traitement de la dépression et de la schizophrénie ;
- autres (3,3%).
La répartition géographique du CA est la suivante : Etats-Unis (63,9%), Europe (18,1%), Japon (4,9%), Chine (4,5%) et autres (8,6%).